mTOR signaling pathway and mTOR inhibitors in cancer therapy

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Mammalian target of rapamycin (mTOR) is a key serine/threonine protein kinase in cellular regulation.
• mTOR pathway dysregulation is implicated in various cancers, making it a significant therapeutic target.
• Current mTOR inhibitors demonstrate modest efficacy as monotherapies in tumors with specific pathway dependencies.

Purpose of the Study:

• To investigate the rationale behind developing dual PI3K/mTOR kinase inhibitors.
• To explore strategies for overcoming resistance to mTOR inhibition in cancer treatment.
• To address the limitations of single-agent mTOR inhibitors by targeting upstream regulators.

Main Methods:

• The study reviews the molecular mechanisms of mTOR signaling and resistance pathways.
• It discusses the design and development of dual PI3K/mTOR inhibitors.
• Preclinical and clinical data on dual inhibitors are analyzed.

Main Results:

• Single-agent mTOR inhibitors show limited success despite targeting specific oncogenic drivers like HiF1α, cyclin D1, or TSC.
• Dual PI3K/mTOR inhibitors aim to circumvent resistance by simultaneously inhibiting PI3K and mTOR.
• This dual inhibition strategy is hypothesized to prevent feedback loop activation that promotes resistance.

Conclusions:

• Dual PI3K/mTOR inhibitors represent a promising therapeutic strategy to enhance anti-cancer efficacy.
• Targeting both PI3K and mTOR pathways may overcome resistance mechanisms observed with mTOR inhibitors alone.
• Further research and clinical trials are warranted to establish the full potential of dual PI3K/mTOR inhibitors in cancer therapy.